IP Library › Granted Patent US 12,338,282
Granted Patent B2
US 12,338,282 · App. 17/450,282 · Granted Jun 24, 2025

Anti-Notch3 antibody

Inventors: Heidi Okamura (Brookline, MA); William M. Winston, Jr. (Marlborough, MA); Laura Poling (Boston, MA); Alisa C. Bell (Bedford, MA)
Assignee: AVEO Pharmaceuticals, Inc.
C07K16/28A61K39/3955A61K39/39558A61P35/00C07K16/2863C07K16/30C12N5/10C12N5/12C12N15/63A61K2039/505C07K14/71C07K2317/21C07K2317/33C07K2317/56C07K2317/565C07K2317/567C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,338,282
App. No.
17/450,282
Granted
Jun 24, 2025
Kind
B2
Abstract

Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation and/or overexpression of Notch3.

Claims (15)

1. A method of inhibiting or reducing ligand-induced Notch3 activity in a mammal, the method comprising exposing the mammal to an effective amount of an antibody that binds human Notch3, wherein the antibody comprises:

(a) an immunoglobulin heavy chain variable region (VH) comprising a CDR H1 , CDR H2 , and CDR H3 , wherein the CDR H1 , CDR H2 , and CDR H3 comprise the CDR H1 , CDR H2 , and CDR H3 of a VH amino acid sequence set forth in SEQ ID NO: 6; and

(b) an immunoglobulin light chain variable region (VL) comprising a CDR L1 , CDR L2 , and CDR L3 , wherein the CDR L1 , CDR L2 , and CDR L3 comprise the CDR L1 , CDR L2 , and CDR L3 of a VL amino acid sequence set forth in any one of SEQ ID NO: 10, 23, 24, 25, 26, 27, 28, 29, 37, 38, or 39.

2. The method of claim 1 , wherein the mammal has a cancer selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, endometrial cancer, ovarian cancer, prostate cancer, cervical cancer, brain cancer, skin cancer, colorectal cancer, gastric cancer, head and neck cancer, gastrointestinal cancer, sarcoma, and hematopoietic cell cancer.

3. The method of claim 2 , wherein the brain cancer is glioblastoma, astrocytoma, or neuroblastoma.

4. The method of claim 2 , wherein the sarcoma is rhabdomyosarcoma or osteosarcoma.

5. The method of claim 2 , wherein the hematopoietic cell cancer is multiple myeloma or leukemia.

6. The method of claim 5 , wherein the leukemia is T-ALL, B-ALL, or B-CLL.

7. The method of claim 1 , wherein the mammal is a human.

8. The method of claim 1 , wherein the amino acid sequence of the VH comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO: 3, a CDR H2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR H3 comprising the amino acid sequence of SEQ ID NO: 5, and wherein the amino acid sequence of the VL comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 21, a CDR L2 comprising the amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 22, and a CDR L3 comprising the amino acid sequence of SEQ ID NO: 9.

9. The method of claim 1 , wherein the amino acid sequence of the VH comprises the amino acid sequence of SEQ ID NO: 6, and wherein the amino acid sequence of the VL comprises the amino acid sequence of SEQ ID NO: 10, 23, 24, 25, 26, 27, 28, 29, 37, 38, or 39.

10. The method of claim 1 , wherein the antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 1, and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 2, 30, 31, 32, 33, 34, 35, 36, 40, 41, or 42.

11. The method of claim 1 , wherein the ligand is selected from the group consisting of Jag1, Jag2, DLL1, and DLL2.

12. The method of claim 1 , wherein the ligand-induced Notch3 activity is ligand-induced Notch3 intracellular domain (ICD) cleavage.

13. The method of claim 1 , wherein the ligand-induced Notch3 activity is ligand-induced Notch3-mediated transcription.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2022
From: OKAMURA, HEIDI; WINSTON, WILLIAM M., JR.; POLING, LAURA; BELL, ALISA C.
To: AVEO PHARMACEUTICALS, INC.
Reel/Frame 058877/0396 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2022
From: OKAMURA, HEIDI; WINSTON, WILLIAM M., JR.; POLING, LAURA; BELL, ALISA C.
To: AVEO PHARMACEUTICALS, INC.
Reel/Frame 058877/0425 →
Continuity (4)
Continuation 16097489
Provisional Application 62460371 · Feb 17, 2017
Provisional Application 62329729 · Apr 29, 2016
Related Publication 20220235127A1 · Jul 28, 2022
References Cited (69)
US 6399857B1 · Kloti · 2002 [cited by applicant]
US 7544476B1 · O'Hagan et al. · 2009 [cited by applicant]
US 7915390B2 · Li · 2011 [cited by examiner]
US 7935791B2 · Fung · 2011 [cited by examiner]
US 7994285B2 · Li · 2011 [cited by examiner]
US 8425903B2 · Gurney et al. · 2013 [cited by applicant]
US 9200071B2 · Siebel · 2015 [cited by examiner]
US 9879083B2 · Okamura · 2018 [cited by examiner]
US 10745476B2 · Okamura · 2020 [cited by examiner]
US 11142573B2 · Okamura · 2021 [cited by examiner]
US 20100111958A1 · Gurney et al. · 2010 [cited by applicant]
US 20130323266A1 · Hoey · 2013 [cited by examiner]
US 20140127211A1 · Geles · 2014 [cited by examiner]
US 20170023576A1 · Cancilla · 2017 [cited by examiner]
WO WO2008091641A2 · 2008 [cited by applicant]
WO WO2010005566A2 · 2010 [cited by applicant]
WO WO2011041336A2 · 2011 [cited by applicant]
WO WO2012003472A1 · 2012 [cited by applicant]
WO WO2014100435A1 · 2014 [cited by applicant]
WO WO2014159239A2 · 2014 [cited by applicant]
WO WO2016046053A1 · 2016 [cited by examiner]
Aburjania et al. The role of Notch3 in cancer. The Oncologist 23: 900-911, 2018. [cited by examiner]
Bellavia et al. Notch3: from subtle structural differences to functional divesity. Oncogene 27: 5092-5098, 2008. [cited by examiner]
Cui et al. Notch3 functions as a tumor suppressor by controlling cellular senescence. Cancer Res 73(11): 3451-3459, 2013. [cited by examiner]
Hosseini-Alghaderi et al. Notch3 in development, health and disease. Biomolecules 10: 485, 2020 (17 total pages). [cited by examiner]
Inder et al. The Notch-3 receptor: a molecular switch to tumorigenesis? Cancer Treat Rev 60: 69-76, 2017. [cited by examiner]
Rusanescu et al. Notch signaling in cardiovascular disease and calcification. Curr Cardiol Rev 4: 148-156, 2008. [cited by examiner]
Song et al. Cancer stem cells—an old idea that's new again: implications for the diagnosis and treatment of brease cancer. Expert Opin Biol Ther 7(4): 431-438, 2007. [cited by examiner]
Tannock and Hill. The Basic Science of Oncology. 1998. New York: McGraw-Hill;; pp. 357-358. [cited by examiner]
Brorson et al. Mutational analysis of avidity and fine specificity of anti-levan antibodies. J Immunol 163: 6694-6701, 1999. [cited by examiner]
Brummell et al. Probing the combining site of an anti-carbohydrate antibody by saturation-mutagenesis: role of the heavy-chain CDR3 residues. Biochem 32(4): 1180-1187, 1993 (abstract). [cited by examiner]
Burks et al. In vitro scanning saturation mutagenesis of an antibody binding pocket. Proc Natl Acad Sci USA 94: 412-417, 1997. [cited by examiner]
Cassett et al. A peptide mimetic of an anti-CD4 monoclonal antibody by rationale design. Biochem Biophys Res Comm 307: 198-205, 2003. [cited by examiner]
Chen et al. J Mol Biol 293: 865-881, 1999. [cited by examiner]
Colman Research in Immunol. 145:33-36, 1994. [cited by examiner]
De Pascalis et al. Grafting and “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. J … [cited by examiner]
Holm et al. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Mol Immunol 44: 1075-1084, 2007. [cited by examiner]
Jang et al. The structural basis for DNA binding by an anti-DNA autobody. Mol Immunol 35: 1207-1217, 1998. [cited by examiner]
Kobayashi et al. Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody. Protein Engineering 12(10): 879-884, 1999. [cited by examiner]
MacCallum et al. Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol 262: 732-745, 1996. [cited by examiner]
Paul, William E., Fundamental Immunology, 3rd Edition, Raven Press, New York, Chapt. 8, pp. 292-295 (1993). [cited by examiner]
Raimondi et al. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21Cip1 expresson and hampers tumour cell growth in vitro and in vivo. Cell Death Different… [cited by examiner]
Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci USA 79: 1979-1983, 1982. [cited by examiner]
Sela-Culang et al. The structural basis of antibody-antigen recognition. Front Immunol 4: 302, 2013 (13 total pages). [cited by examiner]
Vajdos et al. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol 320: 415-428, 2002. [cited by examiner]
Van Nes et al. A Notch3 transcriptional module induces cell motility in neuroblastoma. Clin Cancer Res 19(13): 3485-3494, 2013. [cited by examiner]
Vasudevan et al. A single amino acid change in the binding pocket alters specificity of an anti-integrin antibody AP7.4 as revealed by its crystal structure. Blood Cell Mol Dis 32: 176-181, 2004. [cited by examiner]
Wu et al. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J Mol Biol 294: 151-162, 1999. [cited by examiner]
Zhang et al. Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle. mAbs 7(1): 42-52, 2015. [cited by examiner]
Aste-Amezaga et al., “Characterization of Notch1 Antibodies that Inhibit Signaling of Both Normal and Mutated Notch1 Receptors,” PLoS One. 2010;5(2):e9094. [cited by applicant]
Bellavia et al., “Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis,” Proc Natl Acad Sci USA. 2002;99(6):3788-93. [cited by applicant]
Bellavia et al., “Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice,” EMBO. 2000;19(13):3337-48. [cited by applicant]
Bray, “Notch Signalling: A Simple Pathway Becomes Complex,” Nat Rev Mol Cell Biol. 2006;7(9):678-89. [cited by applicant]
Falk et al., “Generation of anti-Notch antibodies and their application in blocking Notch signalling in neural stem cells,” Methods, 2012;58(1):69-78. [cited by applicant]
Haruki et al., “Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers,” Cancer Res. 2005;65(9):3555-61. [cited by applicant]
Jaye et al., “Isolation of a human anti-haemophilic factor IX cDNA clone using a unique 52-base synthetic oligonucleotide probe deduced from the amino acid sequence of bovine factor IX,” Nucleic Acids Res. 1983;11(8):23… [cited by applicant]
Joutel et. al., “Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis,” Lancet. 2001;358(9298):2049-51. [cited by applicant]
Kopan and Ilagan, “The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism,” Cell. 2009;137(2):216-33. [cited by applicant]
Lewin, “Genes IV,” Cell Press. 1990;Ch. 7:118-120. [cited by applicant]
Li et al., “Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3,” J. Biol. Chem. 2008;283(12):8046-54. [cited by applicant]
Lin et al., “Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer,” Cancer Res. 2010;70(2):632-8. [cited by applicant]
Lloyd et al., “Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens,” Protein Eng Des Sel. 2009;22(3):159-68. [cited by applicant]
Miele et al., “NOTCH Signaling as a Novel Cancer Therapeutic Target,” Curr Cancer Drug Targets. 2006;6(4):313-23. [cited by applicant]
Park et al., “Notch3 gene amplification in ovarian cancer,” Cancer Res. 2006;66(12):6312-8. [cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2017/030156, dated Sep. 8, 2017. [cited by applicant]
Sambrook et al., “Molecular Cloning a Labratory Manual,” 2nd Edition, Cold Spring Harbor, N.Y., 1989;2.43-2.84. [cited by applicant]
Sansone et al., “IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland,” J. Clin Invest. 2007;117(12):3988-4002. [cited by applicant]
Tiyanont et al., “Insights into Notch3 activation and inhibition mediated by antibodies directed against its negative regulatory region,” J. Mol. Biol. 2013;425(17):3192-204. [cited by applicant]
Wu et al., “Therapeutic Antibody Targeting of Individual Notch Receptors,” Nature. 2010;464(7291):1052-7. [cited by applicant]